Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Senti Biosciences has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is ...

On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...

On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...

Tuesday, Wells Fargo (NYSE:WFC) analyst revised the price target for Sangamo BioSciences (NASDAQ:SGMO) to $2.00 from the previous $3.00 while maintaining an Equal Weight rating on the stock. The ...

The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is ...

Sangamo Therapeutics Inc. (NASDAQ:SGMO) received $50 million in upfront payments from Genentech, with the possibility of earning up to $1.9 billion in milestone payments. Caribou Biosciences, Inc ...